安罗替尼联合多西他赛治疗驱动基因阴性晚期非小细胞肺癌的临床疗效研究

Clinical Efficacy of Anlotinib Combined with Docetaxel in Treatment of Driver-negative Advanced Non-small Cell Lung Cancer

目的 探究非小细胞肺癌治疗中安罗替尼与多西他赛联合的作用。方法 选取吉林省肿瘤医院于2022年6月—2023年7月收治的120例非小细胞肺癌患者为研究对象,采用随机摸球法分为两组,各60例。对照组使用多西他赛治疗,研究组联用多西他赛和安罗替尼治疗。对比两组临床疗效、上皮特异性黏附分子(Epithelial Cell Adhesion Molecule, EP-CAM)、可溶性细胞间黏附分子-1(Soluble Intercellular Adhesion Molecule-1, SICAM1)、血清细胞黏附分子(Cellular Adhesion Molecule, CAM)水平及不良反应发生率。结果 研究组的疾病缓解率为43.33%,高于对照组的21.67%,差异有统计学意义(χ^(2)=6.419,P=0.011)。治疗后,研究组EP-CAM、SICAM1、CAM水平低于对照组,差异有统计学意义(P均<0.05)。研究组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论 安罗替尼联合多西他赛治疗驱动基因阴性非小细胞肺癌能够降低肿瘤标志物,且有助于降低不良反应发生风险。

Objective To explore the effect of combined anlotinib and docetaxel in the treatment of non-small cell lung cancer.Methods A total of 120 patients with non-small cell lung cancer admitted to Jilin Cancer Hospital from June 2022 to July 2023 were selected as the study objects and divided into two groups with sixty cases each by ran-dom ball-touching method.The control group was treated with docetaxel and the study group was treated with docetaxel and anlotinib.The clinical efficacy,epithelial cell adhesion molecule(EP-CAM),soluble intercellular adhe-sion molecule-1(SICAM1),the level of cellular adhesion molecule(CAM)in serum and the incidence of adverse reac-tions were compared between the two groups.Results The disease remission rate in the study group was 43.33%,higher than 21.67%in the control group,the difference was statistically significant(χ^(2)=6.419,P=0.011).After treat-ment,the levels of EP-CAM,SICAM1 and CAM in the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).The incidence rate of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The combina-tion of anlotinib and docetaxel in the treatment of driver negative non-small cell lung cancer can reduce tumor mark-ers and reduce the risk of adverse reactions.